OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Gonzalez Velez on the Role of Tarlatamab As Second-Line Treatment For SCLC

June 11th 2025

Miguel Gonzalez Velez, MD, discusses the role of tarlatamab as a second-line treatment for small cell lung cancer.

Dr Pennell on the Significance of the FDA Approval of Taletrectinib for ROS1+ NSCLC

June 11th 2025

Nathan A. Pennell, MD, PhD, discusses the significance of the FDA approval of taletrectinib for ROS1-positive non-small cell lung cancer.

Dr Sabari on c-MET as a Potential Biomarker of Response in EGFR Wild-Type NSCLC

June 11th 2025

Joshua Sabari, MD, explains the rationale behind targeting c-MET in nonsquamous EGFR wild-type advanced NSCLC.

Dr Zhang on Sacituzumab Tirumotecan in Pretreated Advanced EGFR-Mutated NSCLC

June 11th 2025

Li Zhang, MD, discusses sacituzumab tirumotecan in patients with previously treated, advanced EGFR-mutated non–small cell lung cancer.

Dr Kalinsky on Evolving Roles for the CLEOPATRA and DESTINY-Breast09 Regimens in HER2+ Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses potential new roles for the CLEOPATRA and DESTINY-Breast09 regimens in the HER2-positive breast cancer paradigm.

Dr Cristofanilli on the Potential Role of Serial ESR1 Mutation Monitoring in HR+/HER2-Negative Advanced Breast Cancer

June 10th 2025

Massimo Cristofanilli, MD, details the implications of serial ESR1 mutation monitoring using ctDNA in HR-positive/HER2-negative advanced breast cancer.

Dr Mayer on Imlunestrant in HR+/HER2-Negative Advanced Breast Cancer Following Prior Endocrine Therapy

June 10th 2025

Erica L. Mayer, MD, MPH, discusses the use of imlunestrant in HR+, HER2-negative advanced breast cancer following prior endocrine therapy.

Dr Kalinsky on the Importance of Biomarker Testing in HR+/HER2-Negative Advanced Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, discusses the importance of biomarker testing in guiding therapeutic decision-making in HR-positive, HER2-negative breast cancer.

Dr Kalinsky on Efficacy Data From SERENA-6 in ER+/HER2– Advanced Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses data with camizestrant plus a CDK4/6 inhibitor in ER–positive, HER2-negative advanced breast cancer.

Dr Wermke on the Efficacy and Safety of Obrixtamig With Topotecan in Advanced SCLC

June 9th 2025

Martin Wermke, MD, discusses obrixtamig in combination with topotecan for the treatment of patients with advanced small cell lung cancer.

Dr Schmidt on the Role of Minimally Invasive and Robotic Modalities in Bladder Cancer

June 9th 2025

Bogdana Schmidt, MD, MPH, discusses the role of minimally invasive and robotic strategies for the treatment of patients with bladder cancer.

Dr Rugo on QOL Data From SERENA-6 in ER+/HER2– Advanced Breast Cancer

June 9th 2025

Hope S. Rugo, MD, discusses quality of life data from the phase 3 SERENA-6 study.

Dr Luke on the Role of IMA203 in Previously Treated Advanced Cutaneous Melanoma

June 6th 2025

Jason Luke, MD, discusses IMA203 vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.

Dr Rugo on Research Needed to Clarify the Role of T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 6th 2025

Hope Rugo, MD, discusses the application of findings from the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer.

Dr Rugo on Ongoing ADC Investigations Set to Shift Practice in HER2+ Breast Cancer

June 6th 2025

Hope Rugo, MD, discusses the evolving use of antibody-drug conjugates in HER2-positive breast cancer.

Dr Mayer on ESR1 Testing Methods in the SERENA-6 Study of Patients With ER+/HER2– Advanced Breast Cancer

June 5th 2025

Erica L. Mayer, MD, MPH, discusses ESR1 mutation detection by ctDNA liquid biopsy in the phase 3 SERENA-6 study.

Dr Tolaney on the Clinical Implications of First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 5th 2025

Sara M. Tolaney, MD, MPH, details the clinical implications for first-line T-DXd/pertuzumab for the treatment of patients with HER2-positive breast cancer.

Dr Sammons on the Significance of DESTINY-Breast09 for the HER2+ Breast Cancer Treatment Paradigm

June 5th 2025

Sarah Sammons, MD, contextualizes the importance of T-DXd plus pertuzumab within the evolving ADC arsenal for HER2-positive breast cancer.

Dr Haas on 5-Year Outcomes With Adjuvant Pembrolizumab in ccRCC

June 5th 2025

Naomi B. Haas, MD, shares 5-year follow-up data with adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

Dr O’Meara on the Evolving Role of ADCs in HER2+ Breast Cancer

June 4th 2025

Tess O’Meara, MD, highlights the role of antibody-drug conjugates for the treatment of patients with HER2-positive breast cancer.